Kante Aïcha, Chevalier Mathieu F, Sène Damien, Chauffier Jeanne, Mouly Stéphane, Chousterman Benjamin Glenn, Azibani Fériel, Terrier Benjamin, Pezel Théo, Comarmond Cloé
Department of Internal Medicine, Lariboisière Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
INSERM UMR-S 976, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.
Front Immunol. 2025 Jan 17;15:1509782. doi: 10.3389/fimmu.2024.1509782. eCollection 2024.
Auto-immune and inflammatory diseases are heterogenous in their clinical manifestations and prognosis, even among individuals presenting with the same pathology. Understanding the immunological alterations involved in their pathogenesis provides valuable insights in different clinical phenotypes and treatment responses. Immunophenotyping could lead to significant improvements in diagnosis, monitoring, initial treatment decisions and follow-up in autoimmune and inflammatory diseases. Mass cytometry provides measurement of over 40 simultaneous cellular parameters at single-cell resolution, and therefore holds immense potential to evaluate complex cellular systems and for high-dimensional single-cell analysis. The high dimensionality of mass cytometry provides better coverage of immune populations dynamics, with sufficient power to identify rare cell types compared to flow cytometry. In this comprehensive review, we explore how mass cytometry findings contributed in the past decade to a deeper understanding of the cellular actors involved in systemic auto-immune and auto-inflammatory diseases with their respective therapeutic and prognostic impact. We also delve into the bioinformatical approaches applied to mass cytometry to analyze the high volumes of data generated, as well as the impact of the use of complementary single cell RNA sequencing, and their spatial modalities. Our analysis highlights the fact that mass cytometry captures major information on cell populations providing insights on the complex pathogenesis of autoimmune diseases. Future research designs could include mass cytometry findings in association to other -omics to stratify patients in adequate therapeutic arms and provide advancements in personalized therapies in the field of auto-immune and inflammatory diseases.
自身免疫性疾病和炎症性疾病在临床表现和预后方面存在异质性，即使在患有相同病理的个体中也是如此。了解其发病机制中涉及的免疫改变，可为不同的临床表型和治疗反应提供有价值的见解。免疫表型分析可显著改善自身免疫性疾病和炎症性疾病的诊断、监测、初始治疗决策及随访。质谱流式细胞术能够在单细胞分辨率下同时测量40多个细胞参数，因此在评估复杂细胞系统和进行高维单细胞分析方面具有巨大潜力。与流式细胞术相比，质谱流式细胞术的高维度能够更好地覆盖免疫群体动态，有足够的能力识别罕见细胞类型。在这篇综述中，我们探讨了在过去十年中，质谱流式细胞术的研究结果如何有助于更深入地了解参与全身性自身免疫性疾病和自身炎症性疾病的细胞成分及其各自的治疗和预后影响。我们还深入研究了应用于质谱流式细胞术的生物信息学方法，以分析产生的大量数据，以及使用互补单细胞RNA测序及其空间模式的影响。我们的分析突出了这样一个事实，即质谱流式细胞术捕捉了关于细胞群体的主要信息，为自身免疫性疾病的复杂发病机制提供了见解。未来的研究设计可以将质谱流式细胞术的研究结果与其他组学相结合，以便将患者分层到适当的治疗组，并推动自身免疫性疾病和炎症性疾病领域个性化治疗的发展。
